Benperidol

證據等級: L5

預測適應症: 10 個

Benperidol: From Psychotic Disorders to Insomnia

One-Sentence Summary

Benperidol is a potent first-generation (typical) antipsychotic of the butyrophenone class, approved in several European countries for psychotic disorders and the management of deviant sexual behaviour, but holding no MHRA marketing authorisation in the United Kingdom. The TxGNN model predicts it may be effective for Insomnia, with no clinical trials and no published literature currently supporting this direction. The prediction score is high at 98.95%, but mechanistic rationale is weak, all evidence sits at Level 5 (model prediction only), and the overall recommendation across all 10 predicted indications is Hold.

Quick Overview

Item	Content
Original Indication	Not established via MHRA licence; known European approvals cover psychotic disorders and deviant sexual behaviour
Predicted New Indication	Insomnia
TxGNN Prediction Score	98.95%
Evidence Level	L5
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on pharmacological class knowledge, Benperidol is a butyrophenone-type typical antipsychotic — the same structural class as haloperidol — and is considered one of the most potent D2 dopamine receptor antagonists in clinical use. It also carries some affinity for H1 histamine receptors and α1-adrenergic receptors, which produces non-specific central nervous system sedation as a pharmacodynamic side effect rather than a primary therapeutic action.

The TxGNN model appears to have identified this sedative property (mediated partly through H1 antagonism) as a potential mechanistic bridge to insomnia and sleep-initiation disorders. There is precedent within the antipsychotic class for this reasoning: second-generation antipsychotics with substantially higher H1 affinity — most notably quetiapine at low doses — have been studied off-label for insomnia in several health systems, lending superficial plausibility to the hypothesis that CNS-depressant antipsychotics might be repurposed for sleep disorders.

However, the mechanistic case for Benperidol specifically is weak. Its sedation is an unintended side effect rather than a targeted sleep-regulatory action; it does not modulate sleep architecture (REM/NREM cycling) through established mechanisms such as melatonin receptor agonism, GABA-A potentiation, or orexin receptor antagonism. More importantly, the risk-benefit profile of a highly potent D2 antagonist — with substantial extrapyramidal symptom (EPS) burden, QTc prolongation risk, and neuroleptic malignant syndrome potential — is markedly unfavourable when multiple licensed, well-tolerated insomnia therapies already exist. The repurposing value of Benperidol for insomnia is therefore considered low.

Overview of All Ten Predicted Indications

All 10 predictions generated by the TxGNN model are rated L5 with a Hold recommendation. A mechanistic review reveals two classes of concern: weak-rationale predictions (sedation misattributed as therapy) and, more critically, pharmacologically contraindicated predictions in Parkinson’s disease spectrum conditions.

Rank	Predicted Indication	TxGNN Score	Mechanistic Assessment
1	Insomnia	98.95%	Weak — non-specific sedation; safer alternatives available
2	Juvenile onset Parkinson disease 19A	94.44%	⚠️ Contraindicated — D2 blockade directly worsens Parkinson’s disease
3	Acute intermittent porphyria	94.11%	Uncertain — haloperidol (same class) has sparse case report data; AIP trigger risk uncharacterised
4	Sleep disorder, initiating and maintaining sleep	93.68%	Weak — overlaps with Rank 1; same reasoning applies
5	Acute encephalopathy with biphasic seizures (AESD)	90.63%	⚠️ High risk — antipsychotics lower seizure threshold in seizure-prone patients
6	Atypical juvenile parkinsonism	89.32%	⚠️ Contraindicated — same dopaminergic mechanism issue as Rank 2
7	Hereditary late-onset Parkinson disease	87.66%	⚠️ Contraindicated — D2 antagonism is directly opposed to all Parkinson’s treatment goals
8	PLA2G6-associated neurodegeneration (PLAN)	87.45%	Very uncertain — may address neuropsychiatric symptoms but risks worsening motor features
9	Specific developmental disorder	86.17%	No mechanistic support; high EPS risk in paediatric population
10	ADHD, inattentive type	85.94%	Mechanistically opposed — D2 blockade worsens prefrontal dopaminergic hypofunction underlying ADHD

Three of the top 10 predictions (Ranks 2, 6, 7) represent indications in which Benperidol would be pharmacologically contraindicated, suggesting a systematic false-positive bias in the TxGNN knowledge graph when applied to potent D2 antagonists across dopaminergic pathway disease clusters.

Clinical Trial Evidence

Currently no related clinical trials registered for Benperidol in insomnia or any of the 10 predicted indications.

Literature Evidence

Currently no related literature available for Benperidol in insomnia or any of the 10 predicted indications.

UK Market Information

Benperidol does not hold MHRA marketing authorisation in the United Kingdom and is not a marketed product in the UK as of the data cutoff date (April 2026). No licensed indications, approved dosage forms, or product-level information are accessible through the UK regulatory pathway.

Marketing Authorisation Number	Product Name	Dosage Form	Approved Indication
—	No UK-licensed product	—	Not applicable

For reference, Benperidol is authorised in certain EU member states (e.g., Germany under the trade name Glianimon, the Netherlands, and Belgium) for psychotic disorders and for reduction of deviant and antisocial sexual behaviour. Healthcare professionals in the UK requiring access to Benperidol would need to follow the MHRA’s unlicensed medicines pathway (Specials or Named Patient basis).

Safety Considerations

Please refer to the SmPC (available from EMA or national EU regulatory agencies for the authorised European formulations) and the BNF for full safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Full warnings, contraindications, and drug interaction data were not available in this evidence pack. Given Benperidol’s established pharmacological class (butyrophenone typical antipsychotic), prescribers should be aware of the following class-level safety considerations as a minimum: risk of extrapyramidal side effects (acute dystonia, akathisia, drug-induced parkinsonism, tardive dyskinesia); QTc interval prolongation; neuroleptic malignant syndrome; contraindication in Parkinson’s disease and Lewy body dementia; and lowered seizure threshold. A comprehensive safety review against the European SmPC is strongly recommended before any clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial or published literature evidence supporting the use of Benperidol in insomnia or any of the ten TxGNN-predicted indications; the mechanistic rationale for the top prediction is weak and relies on a non-specific sedative side effect rather than a direct therapeutic mechanism. Three of the ten predictions are pharmacologically contraindicated, and the drug is not marketed in the UK, making any domestic clinical development pathway non-trivial.

To proceed, the following would be needed:

Obtain full mechanism of action and receptor binding profile data from DrugBank to characterise repurposing potential systematically
Retrieve and review the European SmPC (from German or Dutch regulatory agencies) to document contraindications, warnings, and drug interactions prior to any clinical programme
Conduct a targeted literature search for haloperidol (closest comparator butyrophenone) in acute intermittent porphyria (Rank 3), which represents the most mechanistically plausible and least contraindicated indication in the list
Commission a formal false-positive analysis of the TxGNN model for D2 antagonists in dopaminergic pathway disease clusters to assess model calibration
If insomnia remains the focus, explore whether Benperidol has a meaningful H1 binding affinity profile compared to quetiapine, as this would determine whether class-level evidence is transferable
Clarify the UK regulatory pathway (MHRA pre-submission advice, Specials licence, or full MA application) before committing to any clinical investment

This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require formal clinical validation before application in practice. Data cutoff: 4 April 2026.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.